Theriva Biologics, Inc. — Form 8-K
Filed July 7, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Spanish regulatory authority AEMPS authorized Theriva to begin VIRAGE2, a Phase 2a proof-of-concept trial with 6 patients evaluating more frequent dosing (≥3 doses, 2 months apart) of VCN-01 combined with standard-of-care chemotherapy in metastatic pancreatic cancer. The trial builds on positive VIRAGE Phase 2b results (112 patients) showing 2 doses of VCN-01 improved overall survival, progression-free survival, and duration of response versus single-dose or chemotherapy alone. Results will inform dosing for a potential future Phase 3 trial.
Why this rating
Early-stage clinical approval is real progress for a $3.9M-market-cap biotech dependent on pipeline development; not transformational but meaningful validation of lead asset pathway.
See more from July 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.